1423803-24-0

Basic information

• Product Name: Apixaban Impurity 12
• Synonyms: Apixaban Impurity 12
• CAS NO: 1423803-24-0
• Molecular Formula: C₂₀H₁₉N₅O₃
• Molecular Weight: 377.4
• Mol File: 1423803-24-0.mol

Chemical Properties

• Boiling Point: 656.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 15.03±0.20(Predicted)
• CAS DataBase Reference: Apixaban Impurity 12(CAS DataBase Reference)
• NIST Chemistry Reference: Apixaban Impurity 12(1423803-24-0)
• EPA Substance Registry System: Apixaban Impurity 12(1423803-24-0)

Safety Data

• Hazardous Substances Data: 1423803-24-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Apixaban Impurity 12 is used as a target for monitoring and control in the production of apixaban, an anticoagulant medication. Its presence can potentially affect the drug's efficacy and safety, necessitating the use of analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry for detection and quantification. Efforts are made to minimize its presence in the final drug product to maintain quality and effectiveness for medical use.

Upstream product

• 159217-89-7 N-Boc-4-iodoaniline 
• 93298-14-7 (4-iodophenyl)carbamic acid phenylmethyl ester 
• 545445-40-7 3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one 
• 4509-90-4 5-bromovaleroyl chloride 
• 100-01-6 4-nitro-aniline 
• 473927-63-8 ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate 
• 104-94-9 4-methoxy-aniline 
• 38560-30-4 1-(4-nitrophenyl)piperidine-2-one 

Downstream Products

• 1437577-94-0 6-(4-(5-bromopentanamido)phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide 
• 1449510-64-8 6-(4-(5-chloropentanamido)phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide 

Relevant articles and documents

Preparation method of apixaban (by machine translation)

L - (3 - methoxyphenyl) 4 - oxo 1 - (4 - nitrophenyl) piperidine -2 - ketone -4 - (V), 1 - 4 -2 - tetrahydro - 111H-pyrazolo [4 - c -3, 3 -] pyridine -4 - formamide (V) are obtained by reductive amination, and 4 -oxo -6 -n-pentanoic acid ester is subjected to reductive amination, and the molecule is subjected to 5 - amidation reaction to form the apixaban 4 - (-4 I). the method comprises the following steps of reductive amination -7 - and acid salt condensation 4 5 - 6-7 - methoxyphenyl) reaction, 3 and carrying out -3 - hydrogenation reduction reaction. The method is simple to operate, safe, green, low in cost, high in selectivity, and high yield and purity of products. (by machine translation)

Process for the preparation of apixaban

A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 μm.

An anti-thrombotic drug [...] method for the preparation of

The invention discloses a preparation method of a compound Apixaban as an anti-thrombotic drug. The method disclosed by the invention comprises the following steps of: with a compound 11 shown as the formula 1 as a starting raw material, subjecting the compound 11 and amino protected paraiodoaniline 19 to coupling reaction in the existence of a cuprous reagent and an inorganic base to obtain a compound 20; subjecting the compound 20 and a compound 21 to [3+2] cyclization-elimination reaction to obtain a compound 22; removing a protecting group of the compound 22 to obtain a compound 23, or subjecting the compound 20 and the compound 21 to [3+2] cyclization reaction, directly carrying out elimination reaction under an acidic condition, and meanwhile, removing the protecting group to obtain the compound 23; subjecting the compound 23 to ammonolysis reaction to obtain a compound 24; subjecting the compound 24 and 5-chlorovaleryl halogen to amidation reaction to obtain a compound 25; and cyclizing the compound 25 under an alkaline condition to obtain the Apixaban, or subjecting the compound 24 and 5-chlorovaleryl bromine to amidation and cyclization two-step one-pot method reaction under the alkaline condition to obtain a target product, namely the Apixaban.

PROCESS FOR THE PREPARATION OF APIXABAN

A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,

AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF

The present invention relates to an improved process for the preparation of apixaban and intermediates thereof. In particular, the invention relates to an improved process for the preparation of an amorphous form of apixaban. The invention also relates to a pharmaceutical composition comprising an amorphous form of apixaban for oral administration as an antithrombotic agent.

SOLID STATE FORMS OF APIXABAN

The present invention is directed to solid state forms of Apixaban, processes for preparing the solid state forms, and pharmaceutical compositions thereof.